Sellas Life Sciences Group Inc. shares rose premarket Wednesday, after the company said it saw promising updated clinical data and initial immunobiological data from an ovarian cancer treatment.
The biopharmaceutical company said updated data from its ongoing Phase 1/2 study of Galinpepimut-S combined with Keytruda to treat WT1+ advanced ovarian cancer showed all patients alive and 45.5% continuing investigational therapy as of the latest follow-up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.